Drug Patent Watch

JANUARY 14, 2025

From mergers and acquisitions to licensing agreements and pricing discussions, these complex interactions demand a unique blend of scientific knowledge, business acumen, and interpersonal skills. These tools offer new opportunities for global collaboration but also present challenges in building rapport and reading non-verbal cues.

Pharmaceuticals 55

Pharmaceuticals Compliance Licensing Licensing 55

The Pharma Data

JANUARY 10, 2021

Chief Executive Officer of MorphoSys, will present at the 39 th Annual J.P. EST. Live audio of the presentation can be accessed from the Media and Investors section under Conferences on MorphoSys’ website, www.morphosys.com. The presentation as well as a replay of the webcast will also be available on MorphoSys’ website.

Clinical Trials 52

Clinical Trials Clinical Development Clinical Supply Trials 52

The Pharma Data

NOVEMBER 18, 2020

Presentations to highlight the OBI-833 Phase 1 clinical study results in non-small cell lung cancer (NSCLC) and the dose escalation cohort. These results will be presented by the lead investigators of OBI Pharma’s novel anti-Globo H therapeutic cancer vaccine, OBI-833. ” Presentation number: 397P / Poster: ID 680.

Vaccine 52

Vaccine Small Molecule Immune Response Hospitals 52

The Pharma Data

DECEMBER 13, 2020

Nasdaq: GMDA), an advanced cell therapy company committed to cures for blood cancers and serious hematologic diseases, today announced that the company conducted a Type B Meeting for omidubicel with the U.S. Gamida Cell is an advanced cell therapy company committed to cures for patients with blood cancers and serious blood diseases.

Licensing 52

Licensing Licensing Clinical Trials FDA 52

The Pharma Data

JUNE 15, 2025

The data, which encompass up to 3 years of follow-up after a single infusion of the treatment, were shared in an oral presentation at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2025, held from June 13–16 in Glasgow, United Kingdom. President and Chief Executive Officer of Intellia Therapeutics.

Treatment 40

Treatment Therapies Licensing Licensing 40

The Pharma Data

JUNE 6, 2025

The data, presented during a late-breaking clinical trials session at the European Renal Association (ERA) Congress in Vienna, Austria, mark a significant clinical advance, highlighting the potential of a novel mechanism of action that targets the underlying immunologic pathways driving IgAN progression.

Trials 40

Trials Treatment FDA Therapies 40

Drug Target Review

FEBRUARY 1, 2024

What challenges has the industry faced in developing and commercialising treatments for neurological diseases, including rare diseases? There are a lot of drug development challenges that are, in some cases, unique to neuroscience, including neurological diseases, psychiatric disorders, and rare diseases affecting the nervous system.

Therapies 104

Therapies Drug Development Disease Clinical Development 104

Drug Target Review

JUNE 3, 2024

How does COUR Pharmaceuticals’ immune-modifying nanoparticle platform differ from traditional approaches to treating immune-mediated diseases? By encapsulating specific self-antigens within our biodegradable nanoparticles, we enable the targeted delivery of the CNPs to antigen-presenting cells (APCs) primarily in the spleen and liver.

Disease 49

Disease Therapies Pharmaceuticals Treatment 49

Drug Target Review

APRIL 14, 2025

This model not only promises a broader market but also presents tangible benefits for patients. coli and yeast, but spirulina presents a new set of considerations. Traditional biologics manufacturing can be complex and expensive, making it difficult to offer affordable therapies for widespread diseases. Its simple in principle.

Therapies 52

Therapies Marketing Drug Development Treatment 52

The Pharma Data

NOVEMBER 10, 2020

The poster presentation, given by Johan Sandin , CSO at AlzeCure, presents how the mechanisms in the research platform Alzstatin work and shows that the target mechanism within the platform is suitable as a new treatment for Alzheimer’s disease. STOCKHOLM , Nov. STOCKHOLM , Nov. in the brain.

Pharmaceutical Companies 40

Pharmaceutical Companies Disease Treatment Pharmaceuticals 40

Drug Hunter

APRIL 20, 2023

The development of a commercial manufacturing process involving deuterated building blocks is notable given the fact that the non-deuterated species has different pharmacology (lower selectivity due to an active metabolite), presenting a significant CMC challenge that needed to be overcome.

Small Molecule 130

Small Molecule Clinical Trials Trials Licensing 130

BioPharma Drive: Drug Pricing

JUNE 23, 2025

Expanding potential uses Emerging research suggests GLP-1 drugs might effectively treat chronic kidney disease, liver conditions, and certain cardiac diseases. Additionally, preserving lean muscle mass during weight loss is a key area of focus to improve patient outcomes.

Treatment 130

Treatment Drugs Therapies FDA 130

The Pharma Data

DECEMBER 14, 2020

15, 2020 (GLOBE NEWSWIRE) — Burning Rock Biotech Limited (NASDAQ: BNR, the “Company” or “Burning Rock”) today announced that it entered into an exclusive licensing agreement with Oncocyte Corporation (NYSE American: OCX) to bring DetermaRx , a risk stratification test for early stage lung cancer patients, to China.

Licensing 52

Licensing Licensing Pharmaceutical Companies Treatment 52

The Pharma Data

JANUARY 5, 2021

RAD011 is a pivotal-trial ready synthetic cannabidiol oral solution with potential utilization in multiple endocrine and metabolic orphan diseases. We intend to use PWS as the anchor indication and will further investigate additional orphan disease opportunities in due course.”. Disease Highlights.

Disease 52

Disease FDA Approval Clinical Trials Trials 52

The Pharma Data

JUNE 28, 2021

Food and Drug Administration (FDA) granted Breakthrough Therapy designation for donanemab, Eli Lilly and Company’s (NYSE: LLY) investigational antibody therapy for Alzheimer’s disease (AD). Dementia due to Alzheimer’s disease is the most common form of dementia, accounting for 60 to 80 percent of all cases 1.

Therapies 40

Therapies Disease Treatment FDA Approval 40

The Pharma Data

MARCH 8, 2021

These preliminary findings were presented today during Science Spotlights TM at the 2021 Conference on Retroviruses and Opportunistic Infections (CROI 2021). Findings from the primary efficacy and safety endpoints and additional secondary objectives will be presented at an upcoming medical meeting. About Ridgeback Biotherapeutics.

Trials 69

Trials Virus RNA Research Laboratories 69

Drug Target Review

APRIL 9, 2024

How has nucleolar stress (NS) been linked to age-related diseases, and what approach did researchers use to investigate its toxicity? The nucleolus (and nucleolar stress) had been previously linked to aging and age-related diseases such as cancer or degeneration.

RNA 64

RNA Cell Biology Clinical Development DNA 64

The Pharma Data

APRIL 20, 2023

These data will be presented at the American Academy of Neurology (AAN) Annual Meeting held in Boston and virtually on April 22-27, 2023. A separate analysis showed that treatment with Kesimpta for up to five years was well-tolerated, with no new or increased safety risks identified 2.

Treatment 40

Treatment Trials Disease Licensing 40

The Pharma Data

JULY 12, 2021

Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Ridgeback Biotherapeutics announced today the presentation of previously announced Phase 2 interim results from two Phase 2/3 clinical trials (MOVe-OUT and MOVe-IN) of molnupiravir (MK-4482/EIDD-2801), an investigational oral antiviral therapeutic.

Clinical Trials 52

Clinical Trials Laboratories Research Laboratories Hospitals 52

The Pharma Data

JANUARY 18, 2021

Potential first-in-class disease-modifying biologic in late-stage clinical studies. a clinical-stage biotechnology company focused on developing treatments for immunological and inflammatory diseases, today announced its launch backed by $80 million Series C financing led by Abingworth LLP.

Disease 40

Disease Science Clinical Development Treatment 40

Drug Target Review

FEBRUARY 28, 2024

2,3 However, unlike αβ T cells, which are activated by the presentation of antigens to their TCRs, γδ T cells do not require antigen presentation to become activated. Human γδ TCR repertoires in health and disease. Normality sensing licenses local T cells for innate-like tissue surveillance. Cells 9(40):800 (2020).

Therapies 105

Therapies Engineering Molecular Biology Science 105

DrugBank

OCTOBER 4, 2024

This involves assessing the strength and breadth of patents, evaluating the potential for future patent challenges, and analyzing the value derived from licensing agreements and royalty streams. The high costs associated with bringing a new drug to market, estimated to be over $2.6

Pharmaceuticals 98

Pharmaceuticals Pharmaceutical Companies Therapies Marketing 98

The Pharma Data

JANUARY 14, 2021

“Buprenorphine is the most important medication in our arsenal for treating opioid use disorder, which is currently one of the most lethal diseases for Americans.” The X-waiver presents a major obstacle to “legitimate” patient access to buprenorphine and other MAT.

Treatment 52

Treatment Licensing Licensing Hospitals 52

SugarCone Biotech

JUNE 10, 2024

4-1BB enhances the response of activated T-cells to “foreign antigens”: protein fragments derived from infected, diseased or cancerous cells that are presented to T cells by antigen-presenting cells (APC). The NIMBY problem I think the “Cancer Immunity Cycle” as originally presented by Chen and Mellman ( 10.1016/j.immuni.2013.07.012

Immune Response 87

Immune Response Production Regulations Clinical Trials 87

The Pharma Data

NOVEMBER 23, 2020

NYSE American: SYN) is a diversified clinical-stage company leveraging the microbiome to develop therapeutics designed to prevent and treat gastrointestinal (GI) diseases in areas of high unmet need. . ROCKVILLE, Md. , 24, 2020 /PRNewswire/ — Synthetic Biologics, Inc. Synthetic Biologics, Inc.

Compliance 52

Compliance Licensing Licensing Clinical Trials 52

The Pharma Data

JULY 29, 2021

Today at the Alzheimer’s Association International Conference © (AAIC © 2021), Eli Lilly and Company (NYSE: LLY) presented two new exploratory analyses of data from the Phase 2 TRAILBLAZER-ALZ study. P-tau217 in blood showed promise as additional biomarker of efficacy- Donanemab treatment led to 24% lowering of P-tau217 from baseline.

Disease 52

Disease Treatment Pharmacokinetics Trials 52

Policy Prescription

MAY 28, 2021

One audience member asks about their loved one who is prescribed the drug Dexilant, a drug that treats gastroesophageal reflux disease. They have been getting it from Canada and are now wondering with this presentation, if that is dangerous.”. and licensed by your state board of pharmacy.” Emphasis added).

Pharmacy 52

Pharmacy Licensing Licensing Online Pharmacies 52

Olympian Clinical Research

JANUARY 5, 2022

When a loved one is diagnosed with Alzheimer’s disease , it can be challenging to know what to do or how to cope. You may first want to understand this degenerative disease so that you can best support your loved one after their Alzheimer’s diagnosis. What is Alzheimer’s Disease? . Learn More About Alzheimer’s Disease.

Clinical Trials 52

Clinical Trials Clinical Research Disease Licensing 52

The Pharma Data

NOVEMBER 11, 2020

“As an orally bioavailable small molecule with broad antiviral activity, SLV213 could be a valuable treatment to meet today’s urgent need to fight COVID-19 as well other life-threatening infectious diseases, such as Chagas disease, Ebola virus disease, and Nipah virus infection.”. About Selva Therapeutics.

Treatment 52

Treatment Small Molecule Virus Pharmacokinetics 52

Drug Target Review

MAY 17, 2024

COMPASS is Pepper’s ML-driven transomics platform that unlocks a functional understanding of disease and drugs transcending traditional expression-based approaches. This holistic approach offers a full-picture understanding of biological systems and how those processes impact untreatable diseases like cancer.

Disease 52

Disease Treatment Licensing Licensing 52

The Pharma Data

OCTOBER 14, 2020

Live Webcast : accessible from the Company’s website at www.eloxxpharma.com under Events and Presentations or with this link: [link]. These premature stop codons have been identified in over 1,800 rare and ultra-rare diseases. WALTHAM, Mass., 15, 2020 (GLOBE NEWSWIRE) — Eloxx Pharmaceuticals, Inc.

Pharmaceuticals 52

Pharmaceuticals RNA Small Molecule Protein Production 52

The Pharma Data

JULY 22, 2021

The estrogen receptor is a well-known disease driver in most breast cancers. Together with Pfizer, we will deploy our PROTAC technology in an effort to help people with this devastating disease.”. Despite advancements in oncology in recent years, considerable unmet need persists in the treatment of HR+ breast cancer.

Targeted Protein Degradation 52

Targeted Protein Degradation Therapies Clinical Trials Treatment 52

The Pharma Data

JANUARY 4, 2021

The program was licensed to Allergan in April 2016 , and Allergan was acquired by AbbVie in May 2020. The outcome of this review is expected to be reported around the time of the Company’s full year results presentation in February 2021. ” About the License Agreement. TOKYO and CAMBRIDGE, England , Jan.

Licensing 40

Licensing Licensing Clinical Trials Disease 40

DrugBank

FEBRUARY 9, 2023

1 Present address: Functional Genomics and Metabolism Research Unit, Department of Biochemistry and Molecular Biology, University of Southern Denmark, Denmark. retrieved the drug targets from DrugBank , which they used to establish the relationship with the disease modules, finally predicting drugs that can target these modules effectively.

Clinical Pharmacology 52

Clinical Pharmacology Molecular Biology DNA Licensing 52

The Pharma Data

JANUARY 31, 2021

On the heels of our recent COVID-19 program initiation in partnership with the NIH, this program adds to our growing infectious disease pipeline supported by collaborations with leading biopharma and renowned institutions.”. (Nasdaq: GILD) and Gritstone Oncology, Inc.

Vaccine 52

Vaccine Science Clinical Trials Licensing 52

The Pharma Data

OCTOBER 18, 2021

under a cooperative development and license agreement. Tofersen is also being studied in the Phase 3 ATLAS study, which is designed to estimate the capability of tofersen to delay clinical onset when initiated in presymptomatic individualities with a SOD1 inheritable mutation and biomarker substantiation of complaint exertion.

Biosimilars 40

Biosimilars Protein Production Licensing Licensing 40

The Pharma Data

AUGUST 5, 2020

A separate post hoc analysis demonstrated that nearly 9 out of 10 patients experienced no evidence of disease activity in the second year of treatment 4. Ofatumumab was originally developed by Genmab and licensed to GlaxoSmithKline. ” These data were published in the August 6, 2020 issue of The New England Journal of Medicine.

Trials 52

Trials Treatment Disease Therapies 52